Brief History of Important Immunologic Discoveries and Developments

Total Page:16

File Type:pdf, Size:1020Kb

Brief History of Important Immunologic Discoveries and Developments Brief History of Important Immunologic Discoveries and Developments Year Event Author(s) 1798 Cowpox vaccination Edward Jenner 1866 Wound disinfection Joseph Lister 1876 Discovery of B. antracis, foundation of Robert Koch bacteriology 1880 Discovery of attenuated vaccine by Louis Pasteur invitro passages 1883 Phagocytosis, cellular immunity theory Elie I. I. Metchnikoff 1888 Discovery of bacterial toxins P. P. Emile Roux and Alexandre E. J. Y ersin 1890 Discovery of antitoxins, foundation of Emil A. von Behring and serotherapy Shibasaburo Kitasato 1894 Immunologic bacteriolysis Richard F. J. Pfeiffer and Vasily I. Isaeff 1894 Discovery of antibody and complement Jules J.B. V. Bordet activity as the active factors in bacteriolysis 1896 Discovery of specific agglutination Herbert E. Durham and Max von Gruber 1896 Agglutination test for the diagnosis of Georges F. I. Widal and typhoid (Widal test) Jean-Marie-Athanase Sicard 1900 Formulation of side-chain theory of anti- Paul Ehrlich body formation 1900 Discovery of A, B, 0 blood groups Karl Landsteiner 1900 Development of complement fixation Jules J.B. V. Bordet and reaction Octave Gengou 1902 Discovery of anaphylaxis Charles R. Richet and Paul Portier 1903 Local anaphylaxis due to antibody- Nicholas M. Arthus antigen complex: Arthus reaction 1903 Discovery of opsonization Almroth E. Wright and Steward R. Douglas 440 Brief History of Important Immunologic Discoveries and Developments Year Event Author(s) 1905 Description of serum sickness Clemens von Pirquet and Bela Schick 1910 Introduction of salvarsan, later neo- Paul Ehrlich and Sahachiro Hata salvarsan, foundation of chemotherapy of infections 1910 Development of anaphylaxis test William Schultz (Schultz-Dale) 1914 Formulation of genetic theory of tumor Clarence C. Little transplantation 1921 Experimental trial with BCG vaccine Albert L. C. Calmette and Camille Guerin 1921 Development of cutaneous anaphylactic Carl W. Prausnitz and Heinz reaction Kiistner 1923 Production of anatoxin (toxoid) by Ramon Gaston formaldehyde treatment 1928 Discovery of penicillin, the first anti­ Alexander Fleming biotic 1935 Discovery of sulfonamides for chemo­ Gerhard Domagk therapy of infections 1935 Discovery of local immunity; oral Alexandre Besredka vaccination 1935-36 Purification of antibodies, quantitative Michael Heidelberger and precipitation reaction Forrest E. Kendall 1937 Evidence for identity of the gene for Peter A. Gorer blood group antigen II with one gene for tumor resistance in the mouse (B-2) 1938 Evidence that antibodies are y-globulins Arne Tiselius and Elvin A. Kabat 1942 Discovery of cellular transfer of delayed Karl Landsteiner and Merrill type hypersensitivity in guinea pigs W.Chase 1942 Fluorescence labeling of antibodies and Albert H. Coons antigens 1942 Introduction of adjuvants Jules T. Freund 1943-44 Establishment of immunologic basis of Peter B. Medawar rejection of normal tissue transplants 1946--48 Theory of congenic mouse lines formu­ George D. Snell lated, first congenic lines initiated, and the term histocompatibility introduced 1945 Development of antiglobulin test for Robin R.A. Coombs, R.R.Race, incomplete Rh antibodies and A. E. Mourant Brief History of Important Immunologic Discoveries and Developments 441 Year Event Author(s) 1945 Description of tolerance (chimerism) in Ray D. Owen dizygotic cattle twins 1946 Development of precipitin test in gels Jaques Oudin 1947 Immunoglobulins as "transporteurs" Pierre Grabar 1948 Development of double immunodiffusion Orjan Ouchterlony and Stephen test in gels D. Elek 1948 Discovery of plasma cells as antibody Astrid E. Fagraeus producing cells 1949 Elucidation of the structure of A, B, 0 Elvin A. Kabat, W. T. J. Morgan, blood group antigens and W. M. Watkins 1952 Description of agammaglobulinemia in Ogdon Carr Bruton human 1952 Discovery of histamine in mast cells James F. Riley and Geoffrey B. West 1953 Development of immunoelectrophoresis Pierre Grabar 1953 Experimental evidence of acquired Milan Hasek immunologic tolerance 1956 Major histocompatibility (H-2) complex George D. Snell in the mouse defined 1956 Discovery of human leukocyte antigen, Jean Dausset later be shown to belong to the major histocompatibility complex of man (HLA) 1956 Experimental induction of autoimmunity Ernest Witebsky and Noel R. Rose 1956 Discovery of allotypes Rune Grubb and Jaques Oudin 1957 Discovery of interferon Jean Lindemann and Alick Isaacs 1957 Discovery of macroglobulins with anti- H. Hugh Fudenberg and Henry body activity G. Kunkel 1957 Discovery of Australia antigen, later Baruch Blumberg shown to be Hepatitis B antigen 1957 Discovery of human slow virus infection Carleton Gajdusek (Kuru) 1959 Introduction of the radioimmune assay Rosalyn Yalow and Solomon A. Berson 1960 Antibody structure Alfred Nisonoff, Gerald Edel- man, Rodney P. Porter, Henry G.Kunkel 1961 Discovery of the thymus as part of the Jaques F. A. P. Miller, Robert immune system A. Good 442 Brief History of Important Immunologic Discoveries and Developments Year Event Author(s) 1963 Development of the plaque formation Nils K. Jerne, Richard J. Henry, test Albert A. Nordin 1963 Ss Locus in the H-2 complex discovered Donald C. Shreffler coding for the C4-complement component 1963 (1953) Histamine release by mast cells in Ivan Mota anaphylaxis 1964 Development of rosette-test G. Biozzi 1965 Discovery of the variable region of anti­ Norbert Hilschmann body molecules 1965 Linkage of MLR reactivity to the HLA Fritz Bach, Kurt Hirschhorn complex discovered 1965 Immune response-l (Ir-1) locus in the Hugh O. McDevitt and Michael mouse discovered Sela 1966 Enzyme labeling of antibodies and S. Avremeas antigens 1966 Discovery of IgE as reaginic antibody Kimishige Ishizaka 1969 Thymus function defined, dichotomy of Jaques F. A. P. Miller and the immune system discovered Graham Mitchell 1969 H-2 antigen isolated Stanley G. Nathenson and Akira Shimada 1969 T helper function in antibody formation N. Avrion Mitchison described (T-B Collaboration) 1969 B lymphocytes as cells with surface­ Benvenuto Pernis bound Ig discovered 1969 Discovery of idiotypes Jaques Oudin 1971-72 Cytotoxic T cells described Jean-Charles Cerrotini, K. Theodor Brunner, Peter Perl­ mann, Hermann Wagner 1971 Discovery of MLR locus linked toHLA Edmond J. Yunis and Bernhard in man Amos 1971 Two-locus model of the mouse MHC George D. Snell, Jan Klein, (H-2) formulated Donald C. Shreffler, Jack Stimpfling 1971 T and B cell tolerance defined Jaques Chiller 1972 T suppressor cells described Richard K. Gershon 1972 Discovery of MHC-restriction of T cell Berenice Kindred and Donald dependent immune responses C. Shreffler 1973 Discovery of Ia antigens Chella S. David, Donald C. Shreffler, Jan Klein, Dietrich G6tze, David H. Sachs Brief History of Important Immunologic Discoveries and Developments 443 Year Event Author(s) 1973 T-B cell collaboration I region restricted David H. Katz and Baruch Benacerraf 1974 Idiotypic network theory formulated Nils K. Jerne 1974 K,D-restriction of cytotoxic T cells Peter Doherty and Rolf Zinker­ discovered nagel 1975 Fusion of myeloma cells with normal, George Kohler and Cesar specific antibody-producing plasma Milstein cells (hybridoma) 1978 Structure of MHC (H-2 and HLA) Stanley G. N athenson, Jack antigens defined Strominger 1978 Macrophage-T cell collaboration Jonathan Sprent I-region restricted 1978-80 Elucidation of immunoglobulin genes; Suzuma Tonegawa generation of diversity is (almost) solved 1980 Smallpox worldwide eradicated World Health Organization (WHO) 1982 CD antigens defined by monoclonal Leukocyte antigen workshop, antibodies Paris (Reinharz) 1983-85 T cell antigen receptor genes elucidated Marrack, Allison Glossary of Immunologic Terms Accessory cells. Lymphoid cells predominantly of cells by cytotropic antibodies following ex­ the monocyte and macrophage lineage which posure to antigen cooperate with T and B lymphocytes in im­ Anergy. The inability to react to an antigen (mi­ mune reactions croorganism) Acquired immunity. Immunity that develops as a Antibody. A protein that is produced as a result result of exposure to a foreigne substrate of the introduction of an antigen and which Activated lymphocytes. Lymphocytes that have has the ability to combine with the antigen that been stimulated by specific antigen or nonspe­ stimulated its production cific mitogen Antibody combining site. That configuration pre­ Adoptive transfer. Transfer of immunity by im­ sent on an antibody molecule which links with munocompetent cells from one animal to an­ a corresponding antigenic determinant other Antibody-dependent cell-mediated cytotoxicity Affinity. Binding strength between antibody and (ADCC). A form of lymphocyte-mediated cy­ antigen in an antibody-antigen reaction totoxicity in which an effector cell kills an anti­ Agglutination. An antibody-antigen reaction in body-coated target cell which a solid or particulate antigen forms a Anticomplementarity. Unspecific complement ac­ lattice with a soluble antibody tivation, i.e., not due to antibody-antigen reac­ Allelic exclusion. The phenotypic expression of a tion single allele in cells containing 2 different al­ Antigen. A substance which can induce a detect­ leles for that genetic locus able immune response when introduced into Allergens. Antigens which give rise to allergic sen­ an animal sitization by IgE antibodies Antigenic determinant (epitope). That area of an Allergy. An overshouting hypersensitivity reac­ antigen which determines the specificity of the
Recommended publications
  • Alfred Nobel
    www.bibalex.org/bioalex2004conf The BioVisionAlexandria 2004 Conference Newsletter November 2003 Volume 1, Issue 2 BioVisionAlexandria ALFRED NOBEL 2004 aims to celebrate the The inventor, the industrialist outstanding scientists and scholars, in a he Nobel Prize is one of the highest distinctions recognized, granting its winner century dominated by instant fame. However, many do not know the interesting history and background technological and T that led to this award. scientific revolutions, through its It all began with a chemist, known as Alfred Nobel, born in Stockholm, Sweden in 1833. Nobel Day on 3 April Alfred Nobel moved to Russia when he was eight, where his father, Immanuel Nobel, 2004! started a successful mechanical workshop. He provided equipment for the Russian Army and designed naval mines, which effectively prevented the British Royal Navy from moving within firing range of St. Petersburg during the Crimean War. Immanuel Nobel was also a pioneer in the manufacture of arms, and in designing steam engines. INSIDE Scientific awards .........3 Immanuel’s success enabled him to Alfred met Ascanio Sobrero, the Italian Confirmed laureates ....4 Lady laureates ............7 provide his four sons with an excellent chemist who had invented Nitroglycerine education in natural sciences, languages three years earlier. Nitroglycerine, a and literature. Alfred, at an early age, highly explosive liquid, was produced by acquired extensive literary knowledge, mixing glycerine with sulfuric and nitric mastering many foreign languages. His acid. It was an invention that triggered a Nobel Day is interest in science, especially chemistry, fascination in the young scientist for many dedicated to many of was also apparent.
    [Show full text]
  • Primer the Complement System
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE providedMagazine by ElsevierR259 - Publisher Connector vascular permeability and the infection. The second category Primer extravasation of plasma. This is in which there is persistent accompanied by the adhesion of formation of immune complexes is leukocytes to vascular endothelium autoimmune disease, in which, by The complement and their emigration into definition, the antigen is a system surrounding tissue. Complement permanent feature of the host. plays an important part in An understanding of how immune Philip Taylor, Marina inflammation, in helping to recruit complexes cause tissue injury effector cells and in promoting the developed from study of such Botto and Mark Walport killing and clearance of pathogens. diseases in humans and animals, and But complement can be both from the induction of experimental The system of plasma proteins called friend and foe. In some immune complex disease. In these complement was so-named because circumstances the activation of situations, immune complexes were it complements the activity of complement in response to immune shown to cause tissue injury through antibody in the lysis of bacteria. It complexes may cause harm: acutely activation of complement, as opsonin has a central role in host defence in the context of massive (binding to complement receptors on against many micro-organisms and in complement activation occurring in leukocytes) and as the source of the modulation of inflammatory patients with overwhelming Gram- anaphylatoxins (stimulating leukocyte reactions, an activity that has been negative bacterial sepsis, and chemotaxis and degranulation). But illuminated by the study of humans chronically, when an antibody the development of gene-targeted with naturally occurring deficiencies response develops in the context of mice with deficiencies of complement of complement.
    [Show full text]
  • Meduni Wien Imagebroschuere
    We shape the future Key numbers IN THE TOP 100 worldwide in the medicine category of leading university rankings 8,000 students outpatient treatments annually at Vienna General Hospital 5,750 employees operations annually, including 750 transplants Doing everything to support health Founded in 1365 as the medical faculty of the University of Vienna and made an independent university in 2004, today MedUni Vienna is among Europe’s most highly respected centres of medical training and research. 2 Focused programmes of study MedUni Vienna has an educational offering that ranges from undergraduate degrees to continuing education courses and PhD programmes. MEDICINE DEGREE DENTISTRY DEGREE PROGRAMME PROGRAMME MEDICAL INFORMATICS PHD PROGRAMMES MASTER’S PROGRAMME POSTGRADUATE APPLIED MEDICAL CONTINUING SCIENCE DOCTORAL EDUCATION COURSES PROGRAMME AND CERTIFICATE COURSES Measurable success Since its establishment as an independent university in 2004, research output has grown at MedUni Vienna. This can be seen in the university’s consistent upward progress in significant rankings including the US News Best Global Universities Rankings and the QS World University Rankings. 3 Gerard van Swieten Carl von Rokitansky Josef Skoda Ignaz Philipp Semmelweis Karl Landsteiner Róbert Bárány 4 City of Medicine Medical pioneers: the Vienna School of Medicine Modern medicine was born in the theories of Ignaz Philipp Jewish heritage or dissident Vienna. Gerard van Swieten, Semmelweis in clinical practice thinkers, and were murdered, personal physician to Empress for the first time anywhere in expelled or forced to flee by Maria Theresa, introduced bed- the world. In the 20th century, the National Socialist regime side teaching into medical edu- Karl Landsteiner and Róbert – among them Sigmund Freud, cation in the 18th century.
    [Show full text]
  • FORMATO PDF Ranking Instituciones No Acadã©Micas Por Sub Ã
    Ranking Instituciones No Académicas por sub área OCDE 2020 3. Ciencias Médicas y de la Salud > 3.02 Medicina Clínica PAÍS INSTITUCIÓN RANKING PUNTAJE USA VA Boston Healthcare System 1 5,000 FRANCE Assistance Publique Hopitaux Paris (APHP) 2 5,000 USA UTMD Anderson Cancer Center 3 5,000 USA Mayo Clinic 4 5,000 USA Memorial Sloan Kettering Cancer Center 5 5,000 USA Dana-Farber Cancer Institute 6 5,000 USA Massachusetts General Hospital 7 5,000 FRANCE Institut National de la Sante et de la Recherche Medicale (Inserm) 8 5,000 USA National Institutes of Health (NIH) - USA 9 5,000 FRANCE UNICANCER 10 5,000 USA Harvard School of Dental Medicine 11 5,000 CANADA University Health Network Toronto 12 5,000 USA Cleveland Clinic Foundation 13 5,000 USA Johns Hopkins Medicine 14 5,000 FRANCE Gustave Roussy 15 5,000 NETHERLANDS Erasmus University Medical Center 16 5,000 GERMANY Helmholtz Association 17 5,000 NETHERLANDS Academic Medical Center Amsterdam 18 5,000 SPAIN CIBER - Centro de Investigacion Biomedica en Red 19 5,000 USA Beth Israel Deaconess Medical Center 20 5,000 SWITZERLAND Roche Holding 21 5,000 CANADA Princess Margaret Cancer Centre 22 5,000 USA H Lee Moffitt Cancer Center & Research Institute 23 5,000 SPAIN Hospital Universitari Vall d'Hebron 24 5,000 BELGIUM University Hospital Leuven 25 5,000 USA NIH National Cancer Institute (NCI) 26 5,000 SPAIN Hospital Clinic de Barcelona 27 5,000 USA Bristol-Myers Squibb 28 5,000 USA Merck & Company 29 5,000 UNITED KINGDOM Royal Marsden NHS Foundation Trust 30 5,000 SOUTH KOREA Seoul National University
    [Show full text]
  • Foundation Block Lecture Three Cell Mediated Immunity
    Foundation Block Lecture Five Hypersensitivity Objectives: • To know that hypersensitivity reactions are over and excessive immune responses that can be harmful to body in four different ways • To be familiar with inflammatory processes in type I hypersensitivity reaction that mediates allergic inflammation • To recognize that type II hypersensitivity deals with immune responses against antigens that are integral part of cell membrane and are usually associated with autoimmune disorders • To know that type III hypersensitivity reactions are mediated by immune complexes and cause vasculitis • To describe type IV hypersensitivity is a purely cell mediated immune response associated with chronic inflammation ● Important. ● Extra notes. ● Females notes ● Males notes. What is hypersensitivity? Protective immunity: desirable reaction. Hypersensitivity: undesirable damaging reaction produced by excessive immune reactions. - Undesirable responses can be mediated by: - Antibody binding to antigens (Types I-III). - Cell mediated reaction to chemicals or proteins (Type IV). Types of hypersensitivity: 4 Types of hypersensitivity responses are classified by GEL AND COOMBS (names of scientists) according to the responding mechanisms, NOT the responding antigens: *From 433 team Type I: 1- Also termed as: - Immediate Hypersensitivity. - Allergic reactions. (e.g. asthma and eczema) - Anaphylactic reactions: severe and rapidly progressing systemic forms which can be quickly life threatening. …..............(causes.vasodilation and hypovolemia which causes heart stop then death) 2- Most people will not react to these allergens but some individuals “atopic” respond by producing large amounts of IgE in …........response to those otherwise harmless substances. 3- Non-allergic individuals respond to these allergens by producing IgG antibodies. 4- Features: - Antibody type: IgE - Cellular components: Mast cells, basophiles & eosinophils - Antigens: Also known as allergens ( antigens with low molecular weight & highly soluble).
    [Show full text]
  • NIH Public Access Author Manuscript Nat Genet
    NIH Public Access Author Manuscript Nat Genet. Author manuscript; available in PMC 2013 October 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Nat Genet. 2013 April ; 45(4): 371–384e2. doi:10.1038/ng.2566. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer Stig E Bojesen1,2,*, Karen A Pooley3,*, Sharon E Johnatty4,*, Jonathan Beesley4,*, Kyriaki Michailidou3,*, Jonathan P Tyrer5,*, Stacey L Edwards6, Hilda A Pickett7,8, Howard C Shen9, Chanel E Smart10, Kristine M Hillman6, Phuong L Mai11, Kate Lawrenson9, Michael D Stutz7,8, Yi Lu4, Rod Karevan9, Nicholas Woods12, Rebecca L Johnston10, Juliet D French6, Xiaoqing Chen4, Maren Weischer1,2, Sune F Nielsen1,2, Melanie J Maranian5, Maya Ghoussaini5, Shahana Ahmed5, Caroline Baynes5, Manjeet K Bolla3, Qin Wang3, Joe Dennis3, Lesley McGuffog3, Daniel Barrowdale3, Andrew Lee3, Sue Healey4, Michael Lush3, Daniel C Tessier13,14, Daniel Vincent13,14, Françis Bacot13,14, Study Group members15, Ignace Vergote16,17, Sandrina Lambrechts16,17, Evelyn Despierre16,17, Harvey A Risch18, Anna González-Neira19, Mary Anne Rossing20,21, Guillermo Pita19, Jennifer A Doherty22, Nuria Álvarez19, Melissa C Larson23, Brooke L Fridley23, Nils Schoof24, Jenny Chang- Claude25, Mine S Cicek26, Julian Peto27, Kimberly R Kalli28, Annegien Broeks29, Sebastian M Armasu23, Marjanka K Schmidt29,30, Linde M Braaf29, Boris Winterhoff31, Heli Nevanlinna32, Gottfried E Konecny33, Diether Lambrechts34,35,
    [Show full text]
  • Medicine Merit Badge Requirements
    Columbia-Montour Council MEDICINE NOTES FOR SCOUTS: LIMITED TO 20 SCOUTS 1. Scouts are required to obtain the Medicine merit badge book, study its contents and be prepared to discuss all requirements with the counselor. 2. All items listed in bold type are prerequisites that MUST be completed prior to the event and emailed to your counselor at least 2 weeks before MBC. 3. Scouts are required to download and use the Workbook, and have all requirements filled out before they arrive the day of the event, which may be downloaded at http://www.MeritBadge.org . 4. Counselor: Ralph Baker 570-271-1049, [email protected] Medicine merit badge requirements 1. Discuss with your counselor the influence that EIGHT of the following people or events had on the history of medicine: a. Hippocrates b. William Harvey c. Antoine van Leeuwenhoek d. Edward Jenner e. Florence Nightingale f. Louis Pasteur g. Gregor Mendel h. Joseph Lister i. Robert Koch j. Daniel Hale Williams k. Wilhelm Conrad Roentgen l. Marie and Pierre Curie m. Walter Reed n. Karl Landsteiner o. Alexander Fleming p. Charles Richard Drew q. Helen Taussig r. James Watson and Francis Crick s. Jonas Salk 2. Explain the Hippocratic Oath to your counselor, and compare to the original version to a more modern one. Discuss to whom those subscribing to the original version of the oath owe the greatest allegiance. 3. Discuss the health-care provider-patient relationship with your counselor, and the importance of such a relationship in the delivery of quality care to the patient. Describe the role of confidentiality in this relationship.
    [Show full text]
  • Development and Evaluation of a Simple Latex Agglutination Test for Diagnosis of Tuberculosis' R
    APPuED MICROBIOLOGY, Oct. 1972, p. 525-534 Vol. 24, No. 4 Copyright 0 1972 American Society for Microbiology Printed in U.S.A. Development and Evaluation of a Simple Latex Agglutination Test for Diagnosis of Tuberculosis' R. V. COLE,2 A. W. LAZARUS, AND H. G. HEDRICK Department of Botany and Bacteriology, College of Life Sciences, Louisiana Tech University, Ruston, Louisiana 71270 Received for publication 1 March 1972 A simple latex agglutination test (SLAT) based on modifications of existing serodiagnostic techniques, in which commercially available reagents are used, was developed for detection of antibodies against Mycobacterium tuberculosis. Tests performed on 553 serum samples from 316 individuals, including 117 bacteriologically confirmed active tuberculosis patients, showed 80% positive titers. Sera from 12 patients with arrested tuberculosis showed 91% positive titers. Nonspecific reactions were noted in 5% of 160 serums from selected normal individuals and patients with diseases other than tuberculosis. The an- tibodies detected by the SLAT method were found to be relatively stable when exposed to low temperatures, whereas high temperatures reduced the antibody titer considerably. Disodium ethylenediaminetetraacetic acid inactivation of serum complement was found to be satisfactory. No variation of tuberculosis antibody titer was noted in tests on multiple specimens from patients whose conditions were stabilized. However, considerable fluctuation was encountered in antibody titers obtained on recently detected individuals. Data obtained in this study indicate that the modified procedures of the SLAT method could replace the tuberculin skin test for simple screening of tuberculosis in adults. The use of tuberculin skin test procedures of serodiagnostic methods for the detection of has been the basis for the detection of new tuberculosis antibodies.
    [Show full text]
  • DMJ.1936.2.1.A02.Young.Pdf (3.644Mb)
    DALHOUSIE MEDICAL JOURNAL 5 A Memorable Conference THE HARVARD TERCENTENARY 1636 - 1936 E. GORDON YOUNG, B.A., M.Sc., Ph.D., F.R.S.C. OMEONE has said that the most valuable and rarest thing in the world S is a new idea. It is the verdict or the intellectual world of science, of art and of music that progress centres largely about the thoughts ex­ pressed by the few great minds of the centuries. The work of the scientists of the world has been likened to a great canvas, the subject of which has been chosen by the few and the first bold lines inserted, but the great mass of colour and detail has been supplied by the many faithful apprentices. It was most fitting that the oldest and greatest of American Universities should celebrate its three hundredth birthday in an intellec­ tual feast and that it should invite to its table as leaders of conversation the greatest minds of the world in those subjects which were proposed for discussion. Harvard.!J.as a magnificent record of intellectual tolerance and its hospitality was open to individuals of all nationalities and all re- ligious and political creeds. To Cambridge thus in the early days of September, 1936, there came, by invitation, a group of about two thousand five hundred American and Canadian scholars to participate in a memorable series of symposia led by a special group of sixty-seven eminent scientists and men of letters from fifteen different countries. These included no fewer than eleven men who had the greatest single distinction in the realms of science and of letters, the Nobel Prize.
    [Show full text]
  • Citrullinated Protein Antibody Paratope Drives Epitope Spreading and Polyreactivity in Rheumatoid Arthritis
    Arthritis & Rheumatology Vol. 0, No. 0, Month 2019, pp 1–11 DOI 10.1002/art.40760 © 2019, American College of Rheumatology Affinity Maturation of the Anti–Citrullinated Protein Antibody Paratope Drives Epitope Spreading and Polyreactivity in Rheumatoid Arthritis Sarah Kongpachith, Nithya Lingampalli, Chia-Hsin Ju, Lisa K. Blum, Daniel R. Lu, Serra E. Elliott, Rong Mao and William H. Robinson Objective. Anti–citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis (RA). While epitope spreading of the serum ACPA response is believed to contribute to RA pathogenesis, little is understood regarding how this phenomenon occurs. This study was undertaken to analyze the antibody repertoires of individuals with RA to gain insight into the mechanisms leading to epitope spreading of the serum ACPA response in RA. Methods. Plasmablasts from the blood of 6 RA patients were stained with citrullinated peptide tetramers to identify ACPA- producing B cells by flow cytometry. Plasmablasts were single-cell sorted and sequenced to obtain antibody repertoires. Sixty-nine antibodies were recombinantly expressed, and their anticitrulline reactivities were characterized using a cyclic citrullinated peptide enzyme- linked immuosorbent assay and synovial antigen arrays. Thirty- six mutated antibodies designed either to represent ancestral antibodies or to test paratope residues critical for binding, as determined from molecular modeling studies, were also tested for anticitrulline reactivities. Results. Clonally related monoclonal ACPAs and their shared ancestral antibodies each exhibited differential re- activity against citrullinated antigens. Molecular modeling identified residues within the complementarity-determining region loops and framework regions predicted to be important for citrullinated antigen binding. Affinity maturation re- sulted in mutations of these key residues, which conferred binding to different citrullinated epitopes and/or increased polyreactivity to citrullinated epitopes.
    [Show full text]
  • New Aspects of Human Trichinellosis: the Impact of New Trichinella Species F Bruschi, K D Murrell
    15 REVIEW Postgrad Med J: first published as 10.1136/pmj.78.915.15 on 1 January 2002. Downloaded from New aspects of human trichinellosis: the impact of new Trichinella species F Bruschi, K D Murrell ............................................................................................................................. Postgrad Med J 2002;78:15–22 Trichinellosis is a re-emerging zoonosis and more on anti-inflammatory drugs and antihelminthics clinical awareness is needed. In particular, the such as mebendazole and albendazole; the use of these drugs is now aided by greater clinical description of new Trichinella species such as T papuae experience with trichinellosis associated with the and T murrelli and the occurrence of human cases increased number of outbreaks. caused by T pseudospiralis, until very recently thought to The description of new Trichinella species, such as T murrelli and T papuae, as well as the occur only in animals, requires changes in our handling occurrence of outbreaks caused by species not of clinical trichinellosis, because existing knowledge is previously recognised as infective for humans, based mostly on cases due to classical T spiralis such as T pseudospiralis, now render the clinical picture of trichinellosis potentially more compli- infection. The aim of the present review is to integrate cated. Clinicians and particularly infectious dis- the experiences derived from different outbreaks around ease specialists should consider the issues dis- the world, caused by different Trichinella species, in cussed in this review when making a diagnosis and choosing treatment. order to provide a more comprehensive approach to diagnosis and treatment. SYSTEMATICS .......................................................................... Trichinellosis results from infection by a parasitic nematode belonging to the genus trichinella.
    [Show full text]
  • Opsonin-Dependent Stimulation of Bovine Neutrophil Oxidative Metabolism by Brucella Abortus Peter C
    Veterinary Microbiology and Preventive Medicine Veterinary Microbiology and Preventive Medicine Publications 2-1988 Opsonin-dependent stimulation of bovine neutrophil oxidative metabolism by Brucella abortus Peter C. Canning U.S. Department of Agriculture Billy L. Deyoe U.S. Department of Agriculture James A. Roth Iowa State University, [email protected] Follow this and additional works at: https://lib.dr.iastate.edu/vmpm_pubs Part of the Veterinary Microbiology and Immunobiology Commons, Veterinary Preventive Medicine, Epidemiology, and Public Health Commons, and the Veterinary Toxicology and Pharmacology Commons The ompc lete bibliographic information for this item can be found at https://lib.dr.iastate.edu/ vmpm_pubs/190. For information on how to cite this item, please visit http://lib.dr.iastate.edu/ howtocite.html. This Article is brought to you for free and open access by the Veterinary Microbiology and Preventive Medicine at Iowa State University Digital Repository. It has been accepted for inclusion in Veterinary Microbiology and Preventive Medicine Publications by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Opsonin-dependent stimulation of bovine neutrophil oxidative metabolism by Brucella abortus Abstract Nonopsonized Brucella abortus and bacteria treated with fresh antiserum, heat-inactivated antiserum, or normal bovine serum were evaluated for their ability to stimulate production of superoxide anion and myeloperoxidasemediated iodination by neutrophils from cattle. Brucella abortus opsonized with fresh antiserum or beat-inactivated antiserum stimulated production of approximately 3 nmol of 0 2 -/106 neutrophils/30 min. Similarly treated bacteria also stimulated the binding of approximately 4.3 nmol of Nal/ 107 neutrophils/h to protein.
    [Show full text]